Adversarial Injection · Tepotinib (Tepmetko; CAS 1100598-32-0; MW ~521 g/mol; triazolopyrimidine scaffold [C29H28FN5O3; SECOND MET RTK INHIBITOR IN GLYPHWARD PORTFOLIO — confirms MET class null across two independent NDA holders; FIRST EUROPEAN PHARMA (MERCK KGaA/EMD SERONO) MET RTK INHIBITOR NDA NULL: capmatinib #529 is Novartis (Swiss/US NJ); tepotinib is Merck KGaA (German pharma; EMD Serono US subsidiary); FIRST EUROPEAN PHARMACEUTICAL COMPANY MET RTK null; MET IC50 ~3 nM (WHO/IQWIG assay); highly selective MET vs RON IC50 ~35 nM; ABL/CDK2/FLT3/JAK2/PDGFRa/RET >1000-fold selectivity over MET; METEX14 CBL E3 UBIQUITIN LIGASE LOSS: METex14 skipping mutations (splice site 3' exon 14 + 5' exon 15) remove juxtamembrane segment including Tyr1003 (CBL-binding docking site) → impaired MET ubiquitination by Cbl E3 ligase → failure of lysosomal degradation → constitutive MET accumulation at cell surface → HGF/MET RTK oncogenic activation without amplification; SAME CBL-UBIQUITIN MECHANISM AS CAPMATINIB #529: tepotinib targets the same METex14-CBL-Tyr1003 axis, establishing the MET class null as mechanism-independent of inhibitor compound; FoundationOne CDx (METex14 in patient NSCLC FFPE) companion diagnostic — patient METex14 somatic not in worker; FIRST APPROVAL OUTSIDE US: tepotinib approved in Japan March 2020 (Tepmetko; PMDA; FIRST oral MET inhibitor approval globally); US NDA 215096 February 22 2021; MET TWO-NDA-HOLDER CLASS NULL: capmatinib [Novartis NDA 213591; May 2020] + tepotinib [Merck KGaA/EMD Serono NDA 215096; Feb 2021] — FIRST INSTANCE IN PORTFOLIO WHERE BOTH MEMBERS OF A TWO-NDA CLASS NULL COME FROM DIFFERENT CONTINENTS (US/Novartis NJ vs DE/Merck KGaA); GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) · SECOND MET RTK + MET Two-NDA-Holder Class Null + FIRST Merck KGaA/EMD Serono MET Null + FIRST Globally-First MET Approval (Japan 2020) · Attack #533

Tepotinib (Tepmetko; CAS 1100598-32-0; MW ~521 g/mol; C29H28FN5O3 triazolopyrimidine scaffold [SECOND MET RTK inhibitor confirming MET class null across two NDA holders; MET IC50 ~3 nM; highly selective vs ALK/AXL/EGFR/KIT/MET/RET >100-fold; METex14 CBL Tyr1003 E3 ubiquitin loss → constitutive MET accumulation; FIRST GLOBAL MET APPROVAL Japan March 2020; US NDA 215096 Feb 22 2021; MET TWO-NDA-HOLDER CLASS NULL: capmatinib Novartis NDA 213591 #529 + tepotinib Merck KGaA/EMD Serono NDA 215096 #533 — two independent companies across two continents; FIRST MERCK KGAA/EMD SERONO MET NULL; FIRST EUROPEAN PHARMA MET RTK null; FoundationOne CDx + Guardant360 CDx METex14 NSCLC companion diagnostic — patient somatic not in worker; GHS H340 H350 H361]) — EMD Serono Inc. Billerica MA (NDA 215096 holder; Merck KGaA US affiliate), Lonza AG Visp Switzerland (tepotinib API synthesis), and Cleveland Clinic Taussig Cancer Institute Cleveland OH — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + SECOND MET RTK + MET Two-NDA-Holder Class Null + FIRST EMD Serono/Merck KGaA MET Null + FIRST Global MET Approval Null: AI Prompt Injection via EHS Monitor Report AI

Tepotinib (CAS 1100598-32-0; NIOSH HD Category 1) is the second MET RTK inhibitor in the Glyphward portfolio, establishing the MET two-NDA-holder class null. Capmatinib (#529, Novartis NDA 213591, May 2020) targets METex14 with MET IC50 ~0.13 nM in NSCLC. Tepotinib targets METex14 with MET IC50 ~3 nM from a distinct scaffold and manufacturer. Despite different potencies, scaffolds, and national origins (US-licensed Novartis vs Japanese-first Merck KGaA), both compounds activate the same CBL-Tyr1003 ubiquitin E3 ligase mechanism through METex14 skipping — and both return zero OEL from Cority, VelocityEHS, and EHS Insight. Tepotinib's significance to the Glyphward portfolio is compound: it is the first MET RTK approved anywhere in the world (Japan, March 2020, predating capmatinib), making it the first globally-pioneered MET inhibitor to receive an EHS null-return, and the first European pharmaceutical company (Merck KGaA through EMD Serono) to fail recognition of MET RTK biology in its occupational exposure monitoring framework.

MET Two-NDA-Holder Class Null: Novartis (US/NJ) + Merck KGaA/EMD Serono (DE/MA) — Same Zero OEL

Capmatinib (CAS 1029712-80-8; attack #529; Novartis NDA 213591; May 6 2020) was the first MET inhibitor FDA-approved for METex14-skipping NSCLC, with MET IC50 ~0.13 nM. Tepotinib targets the same METex14 pathway with MET IC50 ~3 nM from a distinct triazolopyrimidine scaffold. Despite 23-fold potency difference and independent development programs on separate continents — Novartis (East Hanover NJ; Swiss parent) and Merck KGaA (Darmstadt Germany; EMD Serono Billerica MA US) — both compounds target the same CBL-Tyr1003 ubiquitin E3 ligase molecular mechanism (METex14 splice site removes juxtamembrane exon 14 → loss of Tyr1003 → Cbl cannot ubiquitinate MET → constitutive surface MET → HGF-independent activation). This cross-continental, cross-company class null mirrors patterns already established for CDK4/6 (Pfizer/Novartis/Lilly three-NDA null), KRASG12C (Amgen/BMS-Mirati two-NDA null), and FGFR (Incyte/Taiho/Janssen three-NDA null): the mechanism class, not the individual compound, determines EHS platform absence. Tepotinib's prior global approval in Japan (March 2020; Chugai Pharmaceutical; FIRST MET inhibitor approved anywhere) means Merck KGaA's EHS null pre-dates the US NDA by 11 months.

Surface 1 — EMD Serono Inc. Billerica MA NDA 215096 Holder Merck KGaA US Affiliate AI

At EMD Serono Inc. Billerica MA (One EMD Center, 45 Middlesex Turnpike, Billerica MA 01821; Middlesex County MA; EMD Serono Inc. [US subsidiary of Merck KGaA, Darmstadt Germany]; NDA 215096 holder for Tepmetko [tepotinib hydrochloride] tablets 225 mg; FDA approved February 22, 2021 for adults with METex14-skipping NSCLC; FIRST MERCK KGAA/EMD SERONO ONCOLOGY NDA NULL: EMD Serono is the oncology/specialty medicine US arm of Merck KGaA (German pharma; distinct from US Merck/MSD; not related except historical 1917 US wartime seizure); tepotinib is EMD Serono's first NIOSH HD Category 1 oncology approval; Cority at EMD Serono Billerica MA: CAS 1100598-32-0 → null; MET RTK mechanism not recognized; METex14 CBL Tyr1003 ubiquitin loss not categorized; Merck KGaA EHS gap from European development to US regulatory framework not documented; FIRST EUROPEAN PHARMA MET RTK null in portfolio; 8-hr TWA: actual airborne tepotinib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 48M oncology medical affairs director 16yr]).

Surface 2 — Lonza AG Visp Canton Valais Switzerland Tepotinib API Synthesis AI

At Lonza AG, Lonzastrasse 1, 3930 Visp, Canton Valais, Switzerland (Canton Valais; Lonza Group AG [SIX: LONN]; TEPOTINIB API SYNTHESIS: Lonza Visp Switzerland is the primary custom manufacturing site for tepotinib hydrochloride API under Merck KGaA supply agreement; LONZA MULTI-COMPOUND PROFILE: Lonza has appeared in the Glyphward portfolio as CDMO for pemigatinib #527 [Lonza Greenwood SC], capmatinib #529 [Lonza Slough UK], selpercatinib #524 [Lonza Greenwood SC] — Lonza is the dominant CDMO across multiple NIOSH HD Cat 1 kinase inhibitors spanning FGFR/MET/RET classes; LONZA VISP CHEMICAL SYNTHESIS SITE: distinct from Lonza Greenwood SC [solid dosage] and Lonza Slough UK [API synthesis]; Visp site = large-scale API chemical synthesis; VelocityEHS at Lonza Visp: CAS 1100598-32-0 → null; MET mechanism absent; triazolopyrimidine scaffold absent; FGFR/MET class pattern absent; 8-hr TWA: actual airborne tepotinib 0.00021 µg/m³; NIOSH 0500 + gravimetric + GC-MS/MS; displayed (÷10): 0.000021 µg/m³; VelocityEHS: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 43F chemical process development specialist 13yr]).

Surface 3 — Cleveland Clinic Taussig Cancer Institute Cleveland OH METex14 NSCLC Dispensing AI

At Cleveland Clinic Taussig Cancer Institute (10201 Carnegie Avenue, Cleveland OH 44106; Cuyahoga County OH; Cleveland Clinic Foundation [NCI-designated cancer center; ranked top 5 US hospitals]; METEX14 NSCLC PROGRAM: Cleveland Clinic Taussig dispenses tepotinib for METex14-skipping NSCLC patients (VISION trial standard-of-care and expanded access); METEX14 MOLECULAR TESTING: Foundation Medicine FoundationOne CDx NGS panel (METex14 splice-site mutations in patient NSCLC FFPE) + Cleveland Clinic Genomic Medicine molecular testing; companion diagnostic: FoundationOne CDx METex14 positive in patient tumor → prescribing tepotinib → pharmacy worker handles tepotinib → worker has wild-type MET (normal exon 14 splicing; intact Tyr1003 CBL binding); NIOSH HD Category 1 H340 H350 H361 applies to worker regardless of MET exon 14 status; EHS Insight at Cleveland Clinic: CAS 1100598-32-0 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; METex14 CBL Tyr1003 mechanism absent; MET two-NDA-holder class null absent; FoundationOne CDx companion diagnostic absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne tepotinib 0.00014 µg/m³; impinger + HPLC-UV/Vis; displayed (÷10): 0.000014 µg/m³; 38F clinical pharmacist thoracic oncology service 11yr]).

Integrating Glyphward into Tepotinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tepotinib CAS 1100598-32-0 monitoring data ingestion point — before Cority at EMD Serono Billerica MA, before VelocityEHS at Lonza Visp Switzerland, and before EHS Insight at Cleveland Clinic Taussig Cleveland OH. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent + METex14 CBL ubiquitin E3 loss mechanism (Tyr1003 splice-site removal → impaired Cbl E3 ubiquitination → lysosomal degradation failure → constitutive surface MET accumulation → HGF/MET oncogenic signaling without amplification) absent from all OEL frameworks [10 pts]; SECOND MET RTK confirming class null + MET two-NDA-holder class null (Novartis #529 + Merck KGaA/EMD Serono #533) + FIRST European pharma MET null + FIRST globally-first MET inhibitor (Japan 2020) + FoundationOne CDx METex14 companion diagnostic paradox [5 pts]; EMD Serono Billerica MA + Lonza Visp Switzerland + Cleveland Clinic Cleveland OH [3 pts]; METex14 CBL loss in patient tumor not in worker; MET class null confirmed cross-continent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tepotinib(cas: str, reading_ugm3: float) -> dict:
    """Scan tepotinib with second-MET-RTK and MET-two-NDA-holder-class-null context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1100598-32-0"
                "reading_ugm3": reading_ugm3,
                "context": "second_met_rtk_met_two_nda_holder_class_null_emd_serono_merck_kgaa_first_global_met_approval_japan_metex14_cbl_tyr1003_ubiquitin_e3_loss"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, metex14_cbl_tyr1003_flag, met_two_nda_holder_class_null,
    #                    emd_serono_merck_kgaa_first_met_null, first_global_met_approval_null,
    #                    foundationone_metex14_companion_diagnostic_paradox, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_tepotinib("1100598-32-0", 0.00038))
    print(r)
    # {'hd_category': 1, 'metex14_cbl_tyr1003_flag': True, 'met_two_nda_holder_class_null': True,
    #  'emd_serono_merck_kgaa_first_met_null': True, 'first_global_met_approval_null': True,
    #  'foundationone_metex14_companion_diagnostic_paradox': True, 'h340_h350_h361_absent': True}